Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 1999

View Archived Issues

Lorus Therapeutics announces preclinical data on anticancer compound

Ilex Oncology focuses on anticancer drugs

Micrologix Biotech continues preclinical testing on acne drugs

Genelabs Technologies' DARPA drug discovery grant renewed

Gastric antisecretory and gastroprotective compounds in development at Byk Gulden

Merck researchers design tachykinin antagonists particularly useful as antiemetics

FDA awards fast track designation to Trimeris's HIV fusion inhibitor

Antiulcer benzimidazoles discovered by Dr. Reddy's group

Novartis describes new PNP inhibitor series in recent patent literature

Purinoceptor P2 receptor antagonists in early development at Astra

Second-generation NNRTIs show promising resistance profile, pharmacokinetics in preclinical studies

Orphan Medical's Busulfex Injection approved in U.S.

Ex vivo studies explain disappointing results with antiadhesion therapy in stroke patients

Boston Life Sciences identifies a second antiangiogenic molecule

Lubeluzole shows good safety but no efficacy in large trial in acute stroke patients

Sch-217048: potent and selective neurokinin antagonist from natural sources

Ligand receives FDA approval for Ontak as CTCL treatment

Preclinical profile of novel antimigraine agent SB-220453 described

Emadine approved for conjunctivitis in Europe

UCB files NDA for levetiracetam

Kitasato investigators discover new microbial-based compound for atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.